Go Pro
→ Washington Is Broke—Could YOUR Savings Be Next? (From Priority Gold) (Ad)tc pixel Free NVOS Stock Alerts

Novo Integrated Sciences (NVOS) Competitors

$0.0039 0.00 (0.00%)
As of 09/4/2026 01:48 PM Eastern
Compare

NVOS vs. IMAC, BACK, AONCW, BTSGU, and LFMDP

Should you buy Novo Integrated Sciences stock or one of its competitors? Novo Integrated Sciences's main competitors and comparable companies include IMAC (IMAC), IMAC (BACK), American Oncology Network (AONCW), BrightSpring Health Services (BTSGU), and LifeMD (LFMDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Novo Integrated Sciences compare to IMAC?

Novo Integrated Sciences (NASDAQ:NVOS) and IMAC (NASDAQ:IMAC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

5.7% of Novo Integrated Sciences shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by company insiders. Comparatively, 10.0% of IMAC shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, IMAC had 4 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 4 mentions for IMAC and 0 mentions for Novo Integrated Sciences. IMAC's average media sentiment score of 0.07 beat Novo Integrated Sciences' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
Novo Integrated Sciences Neutral
IMAC Neutral

IMAC has a net margin of -75.40% compared to Novo Integrated Sciences' net margin of -121.55%. IMAC's return on equity of -52.17% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Integrated Sciences-121.55% -93.07% -46.28%
IMAC -75.40%-52.17%-34.51%

Novo Integrated Sciences has a beta of 5.79, suggesting that its share price is 479% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market.

IMAC has higher revenue and earnings than Novo Integrated Sciences. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A
IMAC$15.22M0.00-$10.54M-$0.27N/A

Summary

IMAC beats Novo Integrated Sciences on 10 of the 13 factors compared between the two stocks.

How does Novo Integrated Sciences compare to IMAC?

IMAC (NASDAQ:BACK) and Novo Integrated Sciences (NASDAQ:NVOS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

5.8% of IMAC shares are held by institutional investors. Comparatively, 5.7% of Novo Integrated Sciences shares are held by institutional investors. 12.3% of IMAC shares are held by insiders. Comparatively, 10.4% of Novo Integrated Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

IMAC has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. IMAC's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
Novo Integrated Sciences -121.55%-93.07%-46.28%

IMAC has higher earnings, but lower revenue than Novo Integrated Sciences. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.03-$9.42M-$3.12N/A
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A

In the previous week, IMAC's average media sentiment score of 0.84 beat Novo Integrated Sciences' score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Positive
Novo Integrated Sciences Neutral

IMAC has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, Novo Integrated Sciences has a beta of 5.79, suggesting that its stock price is 479% more volatile than the broader market.

Summary

IMAC beats Novo Integrated Sciences on 8 of the 12 factors compared between the two stocks.

How does Novo Integrated Sciences compare to American Oncology Network?

American Oncology Network (NASDAQ:AONCW) and Novo Integrated Sciences (NASDAQ:NVOS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

American Oncology Network has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. American Oncology Network's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
American Oncology NetworkN/A N/A N/A
Novo Integrated Sciences -121.55%-93.07%-46.28%

5.7% of Novo Integrated Sciences shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, American Oncology Network's average media sentiment score of 0.00 equaled Novo Integrated Sciences'average media sentiment score.

Company Overall Sentiment
American Oncology Network Neutral
Novo Integrated Sciences Neutral

American Oncology Network has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Oncology Network$1.34BN/AN/AN/AN/A
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A

Summary

American Oncology Network beats Novo Integrated Sciences on 4 of the 6 factors compared between the two stocks.

How does Novo Integrated Sciences compare to BrightSpring Health Services?

Novo Integrated Sciences (NASDAQ:NVOS) and BrightSpring Health Services (NASDAQ:BTSGU) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

5.7% of Novo Integrated Sciences shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Novo Integrated Sciences' average media sentiment score of 0.00 equaled BrightSpring Health Services'average media sentiment score.

Company Overall Sentiment
Novo Integrated Sciences Neutral
BrightSpring Health Services Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Integrated Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

BrightSpring Health Services has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. BrightSpring Health Services' return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Integrated Sciences-121.55% -93.07% -46.28%
BrightSpring Health Services N/A N/A N/A

BrightSpring Health Services has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A
BrightSpring Health Services$14.37BN/AN/AN/AN/A

Summary

BrightSpring Health Services beats Novo Integrated Sciences on 5 of the 7 factors compared between the two stocks.

How does Novo Integrated Sciences compare to LifeMD?

Novo Integrated Sciences (NASDAQ:NVOS) and LifeMD (NASDAQ:LFMDP) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

In the previous week, Novo Integrated Sciences' average media sentiment score of 0.00 equaled LifeMD'saverage media sentiment score.

Company Overall Sentiment
Novo Integrated Sciences Neutral
LifeMD Neutral

5.7% of Novo Integrated Sciences shares are held by institutional investors. 10.4% of Novo Integrated Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LifeMD has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -121.55%. LifeMD's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Integrated Sciences-121.55% -93.07% -46.28%
LifeMD N/A N/A N/A

LifeMD has higher revenue and earnings than Novo Integrated Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Integrated Sciences$13.52M0.01-$16.17M-$0.87N/A
LifeMD$191.59MN/AN/AN/AN/A

Summary

LifeMD beats Novo Integrated Sciences on 4 of the 6 factors compared between the two stocks.

Get Novo Integrated Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVOS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVOS vs. The Competition

Export
MetricNovo Integrated SciencesHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$77K$9.98B$7.05B$12.88B
Dividend YieldN/A2.59%2.54%9.14%
P/E Ratio0.0034.44271.4425.44
Price / Sales0.014.95626.3791.99
Price / CashN/A24.7128.9235.62
Price / Book0.015.3610.976.44
Net Income-$16.17M$313.25M$3.48B$358.18M
7 Day PerformanceN/A0.79%0.25%0.94%
1 Month PerformanceN/A-0.59%3.29%-0.53%
1 Year PerformanceN/A15.14%23.13%13.76%

Novo Integrated Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVOS
Novo Integrated Sciences
N/A$0.00
flat		N/A+77.3%$77K$13.52MN/A170
IMAC
IMAC
N/A$0.00
flat		N/A-99.3%$13K$15.22MN/A106
BACK
IMAC
N/A$0.00
flat		N/A-99.3%$2K$72.05KN/A180
AONCW
American Oncology Network
N/A$0.00
flat		N/AN/A$0.00$1.34BN/A1,525
BTSGU
BrightSpring Health Services
N/A$199.90
+0.6%		N/A+139.6%$0.00$14.37BN/A35,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NVOS) was last updated on 9/8/2026 by MarketBeat.com Staff.
From Our Partners
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
What Is A Roth Conversion, And How Do I Set One Up?
A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...
SmartAsset | Sponsoredtc pixel
This weekend trading strategy could change your Mondays
Every Monday, trader Tim Sykes opens his account to potential profits as high as $8,780, $9,177, even $16,000....
Tim Sykes | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Musk just exposed the crack in his empire
SpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...
The Oxford Club | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
The Closest Thing to a Virtual AI Monopoly Wall Street Is Ignoring
A little-known company may be building the closest thing to a virtual AI monopoly that Wall Street has yet to ...
Stansberry Research | Sponsoredtc pixel